MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments. It also provides over-the counter and food supplement products under the Neurobion, Bion3, Seven Seas, Nasivin, Femibion, Dolo-Neurobion, Vivera/Floratil, Sangobion, Vigantoletten, Apaisyl, and Kytta brands. In addition, the company offers life science products and services for use in the discovery, development, and manufacture of biotechnological drugs, as well as in research and application laboratories; and specialty chemicals and functional materials for applications consumer electronics, lighting, coatings, printing technology, paints, plastics, and cosmetics. It has strategic alliances with Pfizer Inc., Baylor College of Medicine, Bristol-Myers Squibb Company, Intrexon Corporation, F-star Delta Ltd, Alibaba Health, and Checkmate Pharmaceuticals. The company also has collaboration with the Solvias to offer the PyroMAT system, a MAT kit for pyrogen detection; Immutep Limited; Leap Therapeutics, Inc.; and Pfizer Inc. In addition, MERCK Kommanditgesellschaft auf Aktien has a clinical research collaboration with Daiichi Sankyo Company, Limited to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate; and a strategic alliance with genOway S.A. to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
